RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Agile Therapeutics Stock

Agile Therapeutics P/S 2024

Agile Therapeutics P/S

0.02

Ticker

AGRX

ISIN

US00847L1008

WKN

A1135H

As of Dec 24, 2024, Agile Therapeutics's P/S ratio stood at 0.02, a -95.12% change from the 0.41 P/S ratio recorded in the previous year.

The Agile Therapeutics P/S history

Agile Therapeutics Aktienanalyse

What does Agile Therapeutics do?

Agile Therapeutics Inc is a biopharmaceutical company specializing in the development of women's products. The company was founded in 1997 and is based in Princeton, New Jersey, USA. Agile Therapeutics Inc focuses on manufacturing a unique range of women's products called the Women's Healthcare Division. These products aim to help women maintain their health and well-being by addressing their health issues and improving their quality of life. The products of Agile Therapeutics target various areas, including birth control, menstrual discomfort, and frequent infections. The company offers a variety of products to meet a wide range of needs. An important area in which Agile Therapeutics is active is birth control. The company has developed an innovative transdermal contraception system called Twirla, which is currently approved in the USA. In this system, the hormone Gestodene is absorbed through the skin, preventing pregnancy. The Twirla product is easy to use, safe, and effective. It may also offer several other benefits, such as higher tolerability compared to other contraceptive methods. Agile Therapeutics has also developed other products aimed at improving women's quality of life. This includes the product AG200-15, marketed as a treatment for severe menstrual discomfort. It is a progesterone-based transdermal system that allows for continuous dosing over several weeks, thereby reducing menstrual discomfort. Another product is AG890, marketed as a treatment for frequent vaginal infections such as yeast infections. This system aims to help women prevent or treat these infections and also aids in the prevention of recurring infections. The business model of Agile Therapeutics is based on the development and commercialization of women's products that address a significant need in society. The company enters into strategic partnerships with other companies and institutions to effectively and efficiently market its products. Agile Therapeutics also has a strong presence in research and development. Through intensive research efforts, the company has produced a range of innovative products that are in various stages of testing and trial. Agile Therapeutics works closely with the FDA (Food and Drug Administration) to ensure that its products meet all regulatory requirements. Overall, Agile Therapeutics is an innovative company specializing in the development of women's products. With its focus on the health needs of women, the company aims to improve the quality of life for women worldwide. With a wide range of products and a strong business model, Agile Therapeutics is well-positioned for a promising future. Agile Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Agile Therapeutics's P/S Ratio

Agile Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Agile Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Agile Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Agile Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Agile Therapeutics stock

What is the price-to-earnings ratio of Agile Therapeutics?

The price-earnings ratio of Agile Therapeutics is currently 0.02.

How has the price-earnings ratio of Agile Therapeutics changed compared to last year?

The price-to-earnings ratio of Agile Therapeutics has increased by -95.12% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Agile Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Agile Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Agile Therapeutics affect the company?

An increase in the price-earnings ratio of Agile Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Agile Therapeutics affect the company?

A decrease in the price-earnings ratio of Agile Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Agile Therapeutics?

Some factors that influence the price-earnings ratio of Agile Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Agile Therapeutics pay?

Over the past 12 months, Agile Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agile Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Agile Therapeutics?

The current dividend yield of Agile Therapeutics is .

When does Agile Therapeutics pay dividends?

Agile Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agile Therapeutics?

Agile Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Agile Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agile Therapeutics located?

Agile Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agile Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agile Therapeutics from 12/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/24/2024.

When did Agile Therapeutics pay the last dividend?

The last dividend was paid out on 12/24/2024.

What was the dividend of Agile Therapeutics in the year 2023?

In the year 2023, Agile Therapeutics distributed 0 USD as dividends.

In which currency does Agile Therapeutics pay out the dividend?

The dividends of Agile Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Agile Therapeutics

Our stock analysis for Agile Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agile Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.